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Phosphodiesterase 4 (PDE4) has been suggested to a critical factor in the pathogenesis of inflammation by metabolizing cAMP in human
leukocytes, endothelium and epithelium. The present study aimed at evaluating the PDE4 activity and expression, the relationship between the
inflammation and cAMP- activity in the lungs, and potential interventions of PDE inhibitors and antiinflammatory drugs in the reduction of lung
inflammation and goblet cell hyperplasia in allergic rats. The total leukocyte number and eosinophil number in bronchoalveolar lavegar fluid and
PDE4 activity and expression in lungs significantly increased in OVA-sensitized and challenged allergic rat. Lung histology showed an increased
infiltration of inflammatory cells in the perivascular and peribronchial spaces, structure changes and goblet cell hyperplasia in the OVA-sensitized
and -challenged allergic rats. A significant correlation was observed between the increases in cAMP-PDE activity and inflammation in the lung.
Those OVA-induced changes were prevented by pretreatment with PDE inhibitor in a dose-related patterns and with glucocorticosteroid. We
found an increase in the proportion of PDE4 and PDE4 gene expression, while a decrease in the proportion of PDE3 in the lung of allergic rats.
Incubation with different PDE inhibitors down-regulated OVA-induced cAMP hydrolysis. Our data suggest that PDE4C may play an important
role in the airway inflammation, remodeling and goblet cell hyperplasia after repeated challenge of sensitized rats.
© 2006 Elsevier B.V. All rights reserved.Keywords: Asthma; PDE4s; Piclamilast; Dexamethasone; Indomethacin; Inflammation; Goblet cell hyperplasia; Rat1. Introduction
Cyclic nucleotide phosphodiesterases (PDEs) represent
critical pathways for the degradation of the ubiquitous
intracellular second messenger 3′, 5′-cyclic adenosine mono-
phosphate (cAMP) and/or 3′, 5′-cyclic guanosine monopho-
sphate (cGMP), involved in regulation of cellular functions [1].
PDEs comprise eleven biochemically and pharmacologically
distinct enzyme families (PDEs 1–11), of which PDE4 is cAMP-
specific and encoded by four genes (A, B, C, D) [2]. VariousAbbreviations: PDE, phosphodiesterase; cAMP, 3′, 5′-cyclic adenosine
monophosphate phosphodiesterase; OVA, ovalbumin; BALF, bronchoalveolar
lavage fluid; AB/PAS, Alcian Blue-Periodic Acid Schiff
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doi:10.1016/j.bbadis.2005.12.009isoforms of PDE4 have been shown to interact with other
proteins and lipids, allowing specific isoforms to be targeted to
distinct intracellular sites and signaling complexes within cells
[3]. Experimental and clinical studies demonstrated that
inhibition of PDE4 can attenuate cell inflammatory response
and bronchial hyperresponsiveness [4–8]. It has been suggested
that PDE4 inhibitors may be a potential therapy for chronic
airway diseases such as asthma and chronic obstructive lung
disease, since treatment with PDE4 inhibitors showed better
effects of antiinflammation and immunomodulation [2,9].
Although PDE4 activity was noted to be increased in
circulating leukocytes in asthmatic or allergic patients [10–
15], the role of PDE4 activity in the pathogenesis of asthma
and/or allergy remains unclear. While others observed no
significant change of PDE4 activity in such patients [16–18].
Recently, Singh SP et al. reported that prenatal exposure to
Fig. 1. Experimental protocol of the sensitization with 0.2% ovalbumin (OVA)
and 10% aluminium and repeated inhalation of OA once daily for 7 days from
the day 14 after the sensitization. Animals in control group received saline
aerosol. Piclamilast, dexamethasone and indomechacin or vehicle (1%MC) was
orally administered once a day during the exposure to OVA.
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levels of cAMP in the lung through changes in PDE-4D
activity [19], indicating the importance of altered PDE4
activity. However, there is still a need for understanding the
role of lung PDE4 activity in the development of allergic
asthma. Our previous study demonstrated that cAMP-PDE
activity was elevated in lung tissue harvested from rats
sensitized and challenged with ovalbumin (OVA) [20]. In
order to understand the involvement of PDE4 in antigen-
induced airway inflammation and remodeling, the mRNA
expression of PDE4 subtypes and PDE4 activity in the lung
were investigated in a rat model of asthma after intratracheal
exposure of OVA. We also evaluate the potential effects of
cAMP-PDE or cyclooxygenase activity on the development
of antigen-induced airway inflammation, goblet cell hyper-
plasia, and lung damage, by using a selective PDE4 inhibitor
piclamilast (RP73401, N-(3,5-dichloropyrid-4-yl)-3-cyclopen-
tyl-oxy-4-methoxy benzamide) and a non-selective cycloox-
ygenase inhibitor indomethacin, to compare with those of
antiinflammatory glucocorticosteroid dexamethasone.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats, weighing 150–170 g (Shanghai Laboratory
Animal Center, Chinese Academy Sciences, Grade II, certificate No., 22-
9601018), were maintained on diets free of OVA. All experimental animals used
in this study were under a protocol approved by the Zhejiang Medical
Laboratorial Animal Administration Committee of China.
2.2. Drugs
Piclamilast, Siguazodan (SK and F 94836) and theophylline were kindly
provided by Beijing Joinn Drug Research Center, Professor Han-Liang Zhou
(Medical School of Zhejiang University), and MinSheng Pharmaceutical Co
Ltd. (HangZhou, China). Rolipram, indomethacin, ovalbumin (Grade V),
cAMP, cGMP, phenyl methyl sulfonyl fluoride (PMSF), pepstatin A were
purchased from Sigma (Shanghai, China). Dexamethasone sodium phosphate
(Dex) was from Zhejiang Xuanju Pharmaceutical Co Ltd., Xuanju, China,
methylhydroxylpropyl cellulose (MC) from Zhongmei Huadong Pharmaceutical
Co Ltd. (HangZhou, China), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) from Sangon Biological Engineering Technology and Service Co
Ltd. (Shanghai, China), Coomassie brilliant blue protein reagents from
Jiancheng Bio-Tek Corporation (Nanjing, China), and methanol from Siyou
Pharmaceutical Co Ltd. (Tianjing, China).
2.3. OVA sensitization and challenge
The procedure of animal sensitization and challenge was modified on the
basis of the previous study [21] and the experimental protocol is shown in Fig. 1.
In short, 0.5 mL of an allergen solution containing 0.2% OVA mixed with 10%
aluminium hydroxide gel was injected intraperitoneally, while another 0.5 mL
was divided nine intracutaneous injection sites in the proximity of lymph nodes
in the paws, lumbar regions and the neck on day 0. For the preparation of the
drugs suspensions, the solution of 1% MC were used. The solution of piclamilst
(0.3, 1, 3 or 10 mg/kg, respectively), dexamethasone (0.3 mg/kg), indomethacin
(3 mg/kg), or 1% MC for same volume was intratracheally administered at the
volume of 2 mL/100 g (body weight) for 7 days once a day from 14 days and on
after the sensitization of OVA. Thirty minutes after each administration of
pretreatments, rats were placed in an arosol chamber and arosolly exposed to
either saline (NS) or 1% OVA, generated in a jet nebulizer (particle size 1–5 μm;
PARI MASTER, Starnberg, Germany) for 20 min.2.4. Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed by gently instilling D-Hank'
solution into the lung via a tracheal catheter followed by withdrawal. Such
process was repeated three times with 5 mL D-Hank's as total volume. Total
BAL cells counts were determined with a hemacytometer. Differential cells were
counted after slides were prepared by centrifuged at 1500 rpm for 10 min and
staining with Wright stain. The number of total cells for each sample was then
determined according to the volume of BAL recovered.
2.5. Histology
The lungs were harvested and fixed in the buffered formalin (10%, pH 7.0)
for 48 h. The samples were embedded in paraffin and dehydrated in 70 to 100%
ethanol/xylene. Sections were cut at 2–4 μm thickness, deparaffinized, and
stained with hematoxylin and eosin. Pathological changes in the lungs were
assessed, including the number of eosinophil influx, tissue edema, and epithelial
lesion. Inflammatory changes were graded as normal (scale 0), rare (scale 1),
mild (scale 2), moderate (scale 3), severe (scale 4), as described previously [21].
To analyze airway remodeling, the thickness of the bronchiolar wall was
measured by a pathologic diagram-writing analyzing system (HPIAS-1000,
Wuhan Champion Image Technology Corporation Limited, Wuhan, China).
Goblet cells containing the mucous were identified by staining with Alcian
Blue-periodic acid Schiff (AB/PAS). Positive cells with purple/magenta color
were counted by using Olympus CH-20 photomicroscope at ×400 and expressed
as the number of goblet cells per mm of epithelial layer. Histopathological
assessment was performed blind on randomized sections.
2.6. Tissue homogenates
The lung right lobes were removed and homogenated (DY89-I Homo-
genater, Xinzhi SCITECH research institute, Linbo, China) in ice-cold
hypotonic homogenization buffer and centrifuged (Eppendorf Centrifuge,
5804R, Germany) at 12,850×g for 30 min at 4 °C. The buffer solution
contained 30 mmol/L HEPES, pH 7.4, 1 mmol/L Ethylenediaminetetraacetic
Acid (EDTA), 1 mmol/L β-mercaptoethanol, 2 mmol/L PMSF and 10 g/L
pepstatin A (0.1% Triton X-100). The supernatants were collected and stored at
−80 °C until the further assay PDE activity.
2.7. Assay of PDE activity
The PDE activity was analyzed by a modified method of the previous study
[20] at RP-HPLC (HP1100, agilent, USA). A 10-μL sample was added to the
Eppendorf tubes. Each sample has an inactive copy for control. After addition of
PBS (mmol/L−1: NaCl 137, KCl 2.7, Na2HPO4 8.8, KH2PO4 1.5, CaCl2 1.0, and
MgCl2 1.0, pH=7.4), and 10 μmol/L cAMP and cGMP 20 μL, respectively, the
reaction was allowed to proceed under the incubation at 37 °C for 10 min and
stopped in boiling water for 2 min. The supernatants were collected, and
centrifuged at 12,850×g for 30 min at 4 °C. The amount of cAMP present in 50
μL supernatant was determined by RP-HPLC analysis (Hypersil ODS 4.0×250
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PDE inhibitors, theophylline (non-selective), rolipram (PDE4-selective) and
siguazodan (PDE3-selective) were used to inhibit the cAMP-PDE activity to
analyze the component of cAMP-PDE activity in the lung. Protein was
determined by the Bradford method with bovine serum albumin as a standard
[22]. The results were expressed as nanomolar of PDE activity per milligram of
protein.
2.8. Analysis of PDE4 subtype mRNAs
Total RNA was isolated from the tissue using TRIzol Reagent (Invitrogen,
Carlsbad, CA). Preparation of first-strand cDNA from rat was performed
using First-strand cDNA Synthesis kit (Shanghai Sangon Biological
Engineering Technology and Service, Shanghai, China). Sequences of PCR
primer sets used for PDE4 were used as reported previously, each of the PCR
primer sets was able to detect all known variants derived from the appropriate
PDE4 gene [23,24]. PCR amplification was performed in a PCR buffer [10
mM Tris–HCl, pH 9.0, 100 mM KCl, 80 mM (NH4)2SO4 and 0.1% NP-40]
containing each dNTP at 0.2 mM, 1.5 mM MgCl2, each primer at 500 nM,
and 1 U of Taq DNA polymerase (Sangon) in a total reaction volume of 25
μL for 30 cycles, with the following cycle parameters: denaturing 94 °C for
45 s, annealing 56 °C for 70 s and extension 72 °C for 2 min. After PCR
amplification, 8 μL of each reaction mixture was resolved by electrophoresis
on a 1.5% agarose gel containing ethidium bromide, and the PCR product
bands were quantified by using UVP Gel Documentation system (UVP,
Upland, CA). The levels of PDE4 mRNAs were calculated relative to β-actin.
Under the condition, the PCR product accumulation did not reach plateau
levels (data not shown).
2.9. Statistics
All data were presented as Mean±S.E.M. One-way ANOVA analysis was
used to evaluate the levels of cAMP-PDE activities, bronchial wall thickness and
goblet cell hyperplasia. Statistical Package for the Social Sciences (SPSS) 11.0
was used to evaluate the histological score. A probability of Pb0.05 was
considered significant.3. Results
There was no significant difference in histological
measurements between animals sensitized and challenged
with saline and challenged with OVA or sensitized with OVA
and challenged with saline (data not shown). Data from those
animals were pooled as controls. The number of total cells
(Fig. 2A) and eosinophils (Fig. 2B) in BALF significantly
increased in OVA-sensitized and challenged rats pretreated
with MC, as compared to controls (Pb0.01, respectively).
Pretreatment with piclamilast and dexamethasone significantly
prevented from OVA-induced increased number of both total
leukocytes and eosinophils in BAL fluid (Pb0.05 or less), as
compared to OVA-sensitized and challenged animals pre-
treated with MC, while indomethacin showed inhibitory
effects only on number of leukocytes (Fig. 2A). Number of
total leukocytes and eosinophils in BAL fluid of animals
pretreated with piclamilast at the concentrations of 0.3 mg/kg
and indomethacin was significantly higher than that in
controls. Number of infiltrated eosinophils (Fig. 3A), scores
of tissue edema (Fig. 3B) and epithelial damage (Fig. 3C) in
the lung tissue significantly increased in OVA-sensitized and
challenged animals pretreated with MC, as compared to
controls (Pb0.05, respectively). Pretreatment with piclamilast
showed significant inhibitory effects on OVA induced thesechanges at the concentrations of 1 and 3 mg/kg with a dose-
related pattern. OVA-animals pretreated with dexamethasone
had similar levels to controls, significantly different from
OVA-sensitized and -challenged animals pretreated with MC
(Pb0.01, Fig. 3A, B and C). Animals with indomethacin had
significantly lower number of infiltrated eosinophils than
OVA-animals with MC (Fig. 3A), but still significantly higher
than controls (Pb0.05, respectively). Pretreatment with
indomethacin had not effects on OVA-induced lung tissue
edema (Fig. 3B) and epithelial damage (Fig. 3C).
Levels of bronchial wall thickness and the number of goblet
cells were significantly higher in OVA-challenged animals
pretreated with MC, as compared to controls (Pb0.05, Table 1),
while pretreatment with dexamethasone significantly prevented
from OVA-induced bronchial thickness (Pb0.05, vs. OVA-
challenged rats pretreated with MC), rather than by piclamilast
at the low concentrations and indomethacin. Pretreatment with
either piclamilast or dexamethasone significantly prevented
OVA-induced increased number of goblet cells, as compared to
OVA-challenged animals pretreated with MC (Pb0.05 or 0.01,
respectively, Table 1).
In the lung histology, increased number of infiltrated
eosinophils was observed in peri-bronchial (Fig. 4B) and peri-
vascular (Fig. 4F) tissues of OVA-challenged animals pretreated
with MC. In OVA-animals with MC, monolayer of epithelial
cells on the small airway became multiple and thicker (Fig. 5B)
and goblet cell hyperplasia contained both acid (purple color)
and neutral (magenta) mucins (Fig. 5F). These OVA-induced
histological alterations were obviously prevented by pretreat-
ment with dexamethasone (Figs. 4D and H, 5D and H).
Piclamist at higher doses (3 mg/kg) inhibited the influx of
inflammatory cells in the lung tissue (Fig. 4C and G) and
thickening of the bronchiolar wall in small bronchial (Fig. 5C).
Pretreatment with piclamilast at all doses had partially
inhibitory effects on goblet cell hyperplasia (Fig. 5G), while
indomethacin did not have inhibitory effects on all changes
(Figs. 4E and I, 5E and I).
The cAMP-PDE activity significantly increased in the lung
tissue of OVA-sensitized and challenged rats pretreated with
MC, compared with controls (Pb0.01, Fig. 6). Pretreatment
with piclamilast showed an inhibitory effects on lung cAMP-
PDE with a dose-dependent patter. The similar effects of
dexamethasone (0.3 mg/kg) to piclamilast at the dose of 3 mg/
kg on the inhibition of lung cAMP-PDE activities were noted
with a significant different from OVA rats with MC (Pb0.05,
respectively, Fig. 6), but not indomethacin. In order to
investigate the potential effects of PDE inhibitors on OVA-
induced cAMP-PDE activities, theophylline as a non-selective
PDE inhibitor, rolipram as a PDE4-selective inhibitor and
siguazodan as a PDE3-selective inhibitor were incubated with
the lung homogenates from controls or OVA-sensitized and
challenged rats pretreated with MC. Fig. 7 shows that these
compounds significantly inhibited cAMP-PDE activity at a
concentration-related pattern. Theophylline inhibited the hy-
drolysis of homogenates in the lung from controls or OVA-
challenged rats with a parallel potency. The inhibited hydrolysis
of cAMP was 69% and 84% by theophylline at the
Table 1
Bronchial wall thickness and number of goblet cell in pulmonary tissue of OVA-
challenged rats treated with piclamilast, dexamethasone or indomethacin














0.3 mg/kg 6 0.6±0.1 22.9±2.8*
1 mg/kg 6 0.5±0.0 18.1±5.3*
3 mg/kg 6 0.4±0.0 23.2±3.8*
Dexamethasone-
treated OVA rats
0.3 mg/kg 6 0.3±0.0* 12.2±1.8**
Indomethacin-
treated OVA rats
3 mg/kg 7 0.7±0.1 46.1±4.2
+ and ++ stand for the P values less than 0.05 and 0.01, respectively, as
compared to the control group. * and ** stand for the P values less than 0.05
and 0.01, respectively, as compared to OVA-challenged animals treated with
vehicle.
Fig. 2. The number of total leukocytes (A) and eosinophils (B) in
bronchoalveolar lavage fluid in OVA- or PBS-sensitized and challenged
animals treated with piclamilast (Picl), dexamethasone (Dex) and indomechacin
(Indom) or vehicle (1% MC). + and ++ stand for the P values less than 0.05 and
0.01, respectively, as compared to the control group. * and ** stand for the P
values less than 0.05 and 0.01, respectively, as compared to OVA-challenged
animals treated with vehicle.
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challenged rats, 40% and 70% by rolipram at 10−4 M (Fig. 7B),
and 47% and 20% by siguazodan at 10−4 M (Fig. 7C),
respectively.
Fig. 8 demonstrates lung mRNA levels of PDE4 subtypes
measured by semi-quantitative PCR in controls and OVA-
sensitized and challenged rats. A moderate elevation of PDE4A
and 4B mRNA expression in the lung harvested from OVA-Fig. 3. Eosinophil number (A), tissue edema score (B), and epithelial damage
scores (C) in the lung tissue harvested from OVA- or PBS-sensitized and
challenged animals treated with piclamilast (Picl), dexamethasone (Dex) and
indomechacin (Indom) or vehicle (1%MC). + and ++ stand for the P values less
than 0.05 and 0.01, respectively, as compared to the control group. * and * stand
for the P values less than 0.05 and 0.01, respectively, as compared to OVA-
challenged animals treated with vehicle.sensitized and challenged rats, as shown in Fig. 8A. Expression
of PDE4C mRNA significantly increased after OVA sensitiza-
tion and challenge, as compared with controls (Pb0.01, Fig.
8B). There was a significant correlation between lung cAMP-
PDE activity and the number of leukocytes and eosinophils in
BAL fluid (Spearman's Correlation Coefficient = 0.836,
Pb0.01) and in the lung tissue (Pb0.05).
4. Discussion
Airway inflammation is a critical feature of asthma,
involving mediator release from mast cells and eosinophils
and orchestrating by T cells. Eosinophilic infiltration is a
prominent feature in the pathophysiology of asthma. In
addition, asthma is also characterized by pronounced structural
changes of the bronchial wall associated with inflammatory
process and termed as airway remodeling, such as damage and
shedding of the airway surface epithelium, thickness of the
epithelial reticular basement membrane [25,26]. While excess
mucus secretion not only obstructs airways but also contributes
to airway hyperresponsiveness [27,38]. Potential role of PDE4
in the development of allergical diseases has been investigated
only in human blood leukocytes. Our previous study demon-
strated that cAMP-PDE activity was significant increased in
lung homogenate harvested from antigen-sensitized and
challenged rats [20]. The results from the present study
furthermore suggested that the increase of cAMP-PDE activity
in the lung of OVA-sensitized and -challenged rat may result
from the increased activity of PDE4, since the significant
increase in PDE4 mRNA expression was noted after antigen
challenges.
Little has been known about the mechanism by which
PDE4 gene expression was up-regulated and about the
expression of various PDE4 subtype genes in the lungs after
antigen challenges, although it was shown that different PDE4
subtype genes can undergo distinct regulation [28–30]. cAMP
has been found to induce the expression of various PDE4
subtype genes including 4D5 [28]. In transiently transfected
Fig. 4. Histological alterations of the bronchial mucosal layer (A–E) and perivascular inflammation (E–I) in control animals (A and E), OVA-challenged animals
treated with vehicle (B and F), with piclamilast at the high dose (C and G), with dexamethasone (D and H), or with indomethacin (E and I).
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et al. demonstrated that the PDE4D5 promoter up-regulated
reporter gene expression in response to increased cell cAMP
[3]. Increased cAMP-dependent induction of PDE4D5 tran-
script and activity in primary cultured human airway smooth
muscle cells (hASMs) led to an up-regulation of functional
activity [28]. The inflammatory mediators, lipopolysaccharide,
specifically activates PDE4B gene and PDE4 activity in
peripheral monocytes and neutrophils harvested from mice
deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D
[29,30]. Such response was completely absent in mice
deficient in PDE4B but not PDE4D, indicating that PDE4BFig. 5. Histological alterations of the small airway (A–E) and goblet cells (E–I) in con
with piclamilast at the high dose (C and G), with dexamethasone (D and H), or witgene activation by LPS may constitute a feedback regulation
essential for an efficient immune response. Furthermore,
experimental studies also demonstrated that cigarette smoking
induced chronic pulmonary pathophysiological features in
mice, accompanied by an increased PDE4D gene expression
in the lung [31]. It is possible that the expression and
activation of PDE4 subtypes are highly associated with the
pathological situations. Our results showed that challenge with
antigen could obviously up-regulate expression of the PDE 4C
gene, rather than 4A, 4B and 4D genes. It indicates that the
mechanism by which antigen stimulates these gene expres-
sions via cAMP signaling might be distinct from othertrol animals (A and E), OVA-challenged animals treated with vehicle (B and F),
h indomethacin (E and I).
Fig. 6. Levels of cAMP-PDE activity in the lung harvested from OVA- or PBS-
sensitized and challenged animals treated with piclamilast (Picl), dexametha-
sone (Dex) and indomechacin (Indom) or vehicle (1% MC). + and ++ stand for
the P values less than 0.05 and 0.01, respectively, as compared to the control
group. * and * stand for the P values less than 0.05 and 0.01, respectively, as
compared to OVA-challenged animals treated with vehicle.
Fig. 8. PDE4 subtype mRNA expression (A) and levels (B) in the lungs
harvested from OVA- or PBS-sensitized and challenged animals treated with
piclamilast (Picl), dexamethasone (Dex) and indomechacin (Indom) or vehicle
(1% MC). ** stands for the P values less than 0.01, as compared to OVA-
challenged animals treated with vehicle.
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regulation of gene expression and overactivation of PDE4 in
the lung tissues harvested from antigen challenged rats,
obviously correlated with the development of antigen-induced
lung inflammation. Of its subtypes, PDE4C maybe play an
important role in PDE4-involved inflammation.
Piclamilast as a selective PDE 4 inhibitor has been shown
to inhibit eosinophil adhesion and migration in the in vitro
system with a dose-dependent pattern [32], have potent and
long-acting effects on relaxation of human bronchial muscle
[33], and modulate tissue remodeling associated with lung
inflammatory processes including asthma [34]. The results
from the present study demonstrated that pretreatment with
piclamilast significantly attenuated eosinophilic infiltration
and sequential goblet cell hyperplasia induced by OVA in a
dose-related manner. The inhibitory effect of piclamilast at
the high concentration was equivalent to that of dexameth-
asone on OVA-induced eosinophil infiltration, while more
potent than dexamethasone on cAMP-PDE activity. ItFig. 7. Inhibitory effects (%) of theophylline (A), rolipram (B) and SKF94836 (C) on
sensitized and challenged animals treated with piclamilast (Picl), dexamethasone (D
values less than 0.05 and 0.01, respectively, as compared to the control group. * and
OVA-challenged animals treated with vehicle.suggests that selective PDE4 inhibitor can be competitive
to bind the active site of PDE4 and inhibit the activity, but
dexamethasone potently suppressed the PDE activity by
other mechanisms, e.g., inhibition of protein synthesis [35].
Our results also indicate that cAMP-PDE activity plays, at
least partially, an important role in the development of
antigen-induced goblet cell hyperplasia. Although there is
evidence that COX-2 may be a key element in the
pathophysiological process of asthma [36,37], the present
study failed to show preventive effects of indomethacin on
PDE activity and goblet cell hyperplasia.
Our results demonstrate that goblet cell hyperplasia is
associated with the infiltration and activation of eosinophils,
similar to the previous findings [20]. Furthermore, cAMP-PDE
activity is critical in the development of lung inflammation,
injury and remodeling, since PDE inhibition prevented from
eosinophil infiltration from the circulation to the lung tissue and
alveolar space, lung edema, and increased airway wall thicknessthe cAMP-PDE activity in the lung homogenate harvested from OVA- or PBS-
ex) and indomechacin (Indom) or vehicle (1% MC). + and ++ stand for the P
** stand for the P values less than 0.05 and 0.01, respectively, as compared to
531H.-F. Tang et al. / Biochimica et Biophysica Acta 1762 (2006) 525–532and number of goblet cells. Of PDEs, PDE4 may play a key role
in antigen-induced alterations, evidenced by that PDE4
comprises a higher proportion of the cAMP hydrolyzing
activity in homogenates from OVA-sensitized and challenged
rats. The increased cAMP-PDE activity might be, at least in
part, due to enhanced PDE4 gene expression by antigen
sensitization and challenge.
In conclusion, our results demonstrate that the inhibition of
cAMP-PDE activity prevented from antigen-induced eosinophil
infiltration, lung tissue injury, increased airway wall thickness,
and goblet cell hyperplasia. Pretreatment with piclamilast could
inhibit OVA-induced cAMP-PDE activity in the lung with as a
dose-related pattern. This study suggests that PDE4 may be an
important therapeutic target for antigen-associated lung inflam-
mation and tissue remodeling.
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